(Q36341538)

13 August 2017

1 reference

title

Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer (English)

1 reference

13 August 2017

1 reference

angiogenesis inhibitor

1 reference

1

Jens Gille

1 reference

13 August 2017

Konstanze Spieth

2

1 reference

13 August 2017

Roland Kaufmann

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

26-32

1 reference

Clinical translation of angiogenesis inhibitors

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Promises and pitfalls of anti-angiogenic therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Cytotoxic drugs: the search for dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Metastatic melanoma: chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

The microenvironment of the tumour-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1439-0353.2005.04048.X

10.1046/J.1439-0353.2005.04048.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference